Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sunitinib works in treating patients with
myelodysplastic syndromes or chronic myelomonocytic leukemia. Sunitinib may stop the growth
of abnormal cells by blocking some of the enzymes needed for cell growth.